Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials
Urias, Eduardo , Lee, Jaehoon , Weil, Christopher R. , Roach, Eric , Hashibe, Mia, Facciabene, Andrea , Maity, Amit , Tao, Randa , Weil, Christopher R , Lloyd, Shane

BMJ Oncology | May 8, 2025 | Volume: 4 | Issue: 1 | Pages: e000732

10.1136/bmjonc-2025-000732 | PMID 40357050 Get It

Objective To pool data from prospective clinical trials investigating combined stereotactic ablative radiotherapy (SABR) with immune checkpoint inhibitors (ICI) in patients with metastatic cancers. Methods and analysis PubMed, Scopus and EMBASE were queried for full-length articles of prospective clinical trials involving patients with metastatic solid tumours. Random-effects meta-analysis was performed with the Knapp-Hartung method. Multilevel regression analyses with primary cancers used as random effects and pairwise comparisons with two-tailed test adjusted with Benjamini-Hochberg method were performed. Regression coefficients (β) were calculated to assess the correlation between dose and outcomes. Results We identified 30 trials and 35 individual treatment arms with a total of 951 patients with at least one outcome metric reported. Large heterogeneity was identified for all outcomes measured (I 2 range: 75%–86%). The pooled rate of grade 3+ treatment-related adverse events was 18% (95% CI 11% to 24%). The progression-free survival (PFS) and overall survival (OS) at 6 months were 27% (95% CI 19% to 36%) and 67% (95% CI 59% to 76%), respectively. On multilevel regression, we identified improvement in 6-month PFS (β=0.6, p=0.003) and OS (β=1.6, p=0.04) with increasing BED10Gy doses. Combined-target ICI correlated with better 6-month OS when compared with αPD-1/PD-L1 alone. Conclusion We report a safety profile of combined ICI with SABR in patients with metastatic cancer that is comparable to that of ICI alone. We identified higher doses of radiotherapy and dual-target ICI to be associated with better OS at 6 months. Large heterogeneity and the lack of a control group limit the interpretation of our findings.
Safety and efficacy of MicroPulse transscleral laser therapy with the revised P3 delivery device: A randomized controlled trial
Lentz, P. Connor , Wagner, Isabella V. , Kumar, Devesh , Boopathiraj, Nithya , Ahuja, Abhimanyu S. , Checo, Leticia , Miller, Darby D. , Dorairaj, Syril , Ahuja, Abhimanyu , Checo, Leticia , Miller, Darby D , Dorairaj, Syril , Wagner, Isabella V , Lentz, P Connor , Ang, Bryan C H

European Journal of Ophthalmology | May 8, 2025 | Volume: 35 | Issue: 5 | Pages: 1863-1874

10.1177/11206721251340102 | PMID 40336295 Get It

Objective To evaluate the safety and efficacy of MicroPulse Transscleral Laser Therapy (MicroPulse TLT) with the Revised P3 ® Delivery Device. Design Prospective, single-surgeon, interventional study in a tertiary hospital setting. Participants Sixty-two eyes of 40 patients with refractory glaucoma. Methods All subjects received 360-degree MicroPulse TLT treatment (2500 mW, 31.33% duty cycle) over a total of 240 s (8 sweeps; n = 20), 300 s (10 sweeps; n = 22), or 200 s (10 sweeps; n = 20). Participants were followed up for 6 months to assess changes in intraocular pressure (IOP), glaucoma medication burden, and best-corrected visual acuity (BCVA). Surgical success was defined as a reduction of IOP ≥ 30% from baseline and between 6–18 mmHg at last follow-up with no additional anti-glaucoma medications or secondary reinterventions. Results Surgical success was achieved in 72.7% (300 s group), 75.0% (240 s group), and 80.0% (200 s group) of eyes. Mean IOP was significantly reduced ( p < 0.001) by 49.0% (300 s group), 45.66% (240 s group), and 39.8% (200 s group) at 6 months. With all groups combined, the mean number of glaucoma medications was significantly reduced by 17.8% ( p = 0.005), and no significant changes in BCVA were observed at 6 months. Complications were minimal, including four eyes with IOP spikes, one eye with hyphema, and one eye with cystoid macular edema (CME), all of which resolved. Two eyes of the total sample (3.2%) required secondary glaucoma surgery before 6 months. Conclusions Second-generation MicroPulse TLT at fluence values of 154–229 J/cm 2 appears to be a safe and effective option for IOP reduction in refractory glaucoma.
Kidney aging and chronic kidney disease—another perspective
Glassock, Richard J. , Đenić, Aleksandar , Denic, Aleksandar , Delanaye, Pierre , Rule, Andrew D. , Delanaye, Pierre

Nephrology Dialysis Transplantation | May 7, 2025 | Volume: 40 | Issue: 8 | Pages: 1455-1457

10.1093/ndt/gfaf087 | PMID 40336145 Get It

Self-Motion Perception Influences Postural Sway More than Environmental Motion Perception
Critelli, Kyle, Carpenter, Mark G. , Anson, Eric R , Chen, Edward , Staab, Jeffrey P. , Crane, Benjamin Thomas

No container title available | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.02.651511 | PMID 40655001 Get It

Abstract Motion of the visual field can alter postural sway and cause illusions of self-motion. The relative perceptual sensitivity of self-motion versus visual field motion induced by virtual reality (VR) stimulation and whether observable sway differs based on perceptual task is unknown. Methods to quantify sway perception while concurrently measuring sway do not exist. We measured head sway and motion perception (self or world) in healthy adults who stood with feet together wearing a VR headset while experiencing adaptive staircases of virtual sinusoidal pitch rotation about the ankle axis. In separate conditions of randomly ordered blocks, subjects were asked to indicate (yes/no) if the room moved (regardless of perceived postural sway) or if their postural sway increased (regardless of perceived room motion). Head sway area was measured by tracking movement of the VR headset. Yes/No responses were fit with psychometric curves to determine points of subjective equality (PSEs) for room motion and postural sway. PSEs were compared between conditions. Effects of motion perception (binary responses) on head sway area before, during, and after visual stimulation were examined. The mean PSE for room motion (0.42 degrees) was significantly lower than for postural sway (2.02 degrees) [t(1,18) = 4.4714, p = 0.00029]. Head sway area was significantly larger during (z = 11.53, p < 0.001) and after (z = 5.09, p < 0.001) visual stimulation only when participants perceived increased postural sway. Nearly 5-fold greater amplitudes of oscillating VR visual stimuli were required to induce perceptions of altered self-versus visual field motion. Observed head sway during visual motion was only linked to perceptual responses when participants focused internally on self-motion, not externally on room motion.
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia
Tefferi, Ayalew , Fathima, Saubia , Abdelmagid, Maymona, Alsugair, Ali, Aperna, Fnu, Rezasoltani, Mahsa , Yousuf, Muhammad , Natu, Anuya , Csizmar, Clifford M. , Gurney, Mark E. , Finke, Christy M. , Chien, Kelly S. , Bazinet, Alexandre , Kadia, Tapan M. , Mangaonkar, Abhishek A. , Pardanani, Animesh , Zepeda‐Mendoza, Cinthya , Reichard, Kaaren K. , He, Rong , Sasaki, Koji , Garcia‐Manero, Guillermo , Gangat, Naseema , Montalban‐Bravo, Guillermo , Patnaik, Mrinal M. , Alsugair, Ali Khalid A, Gurney, Mark , Kanagal-Shamanna, Rashmi , Hammond, Danielle , Chien, Kelly , DiNardo, Courtney , Daver, Naval , Zepeda-Mendoza, Cinthya, He, Rong , Loghavi, Sanam , Sasaki, Koji , Larson, Dirk , Onida, Francesco , Gangat, Naseema , Patnaik, Mrinal , Csizmar, Clifford , Fathima, Saubia , Lasho, Terra L. , Kanagal‐Shamanna, Rashmi , Hammond, Danielle , DiNardo, Courtney D. , Daver, Naval , Borthakur, Gautam , Loghavi, Sanam , Passamonti, Francesco , Ravandi, Farhad , Larson, Dirk R.

Blood Journal | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2024027170 | PMID 40332442 Get It

We sought to develop a survival model in chronic myelomonocytic leukemia (CMML) that is primarily based on clinical variables and examine additional impact from mutations and karyotype. 457 molecularly-annotated patients were considered. Multivariable analysis identified circulating Blasts ≥2% (1 point), Leukocytes ≥13 x 109/L (1 point), and severe (2 points) or moderate (1 point) Anemia as preferred risk variables in developing a clinical risk Stratification Tool for overall survival (OS), acronymized to "BLAST": low-risk (0 points; median 63 months); intermediate-risk (1 point; median 28 months; HR 2.2, 95% CI 1.6-3.0), and high-risk (2-4 points; median 13 months; 5.4, 4.1-7.3); the corresponding 3/5 year OS rates were 68%/53%, 43%/18%, and 12%/1%. BLAST model performance (AUC 0.77/0.85 at 3/5-years) was shown to be comparable to that of the molecular CMML-specific prognostic scoring system (CMML-mol; AUC 0.73/0.75) and the international prognostic scoring system-molecular (IPSS-M; AUC 0.73/0.74). Multivariable analysis of mutations and karyotype identified PHF6MUT and TET2MUT as being "favorable" and DNMT3AMUT, U2AF1MUT, BCORMUT, SETBP1MUT, ASXL1MUT, NRASMUT, PTPN11MUT, RUNX1MUT, TP53MUT, and adverse karyotype, "unfavorable". Molecular information was subsequently encoded in a combined clinical-molecular risk model (BLAST-mol; AUC 0.80/0.86 at 3/5-years) that included the aforementioned BLAST clinical risk variables and a 3-tiered molecular risk score. BLAST and BLAST-mol were subsequently validated by two separate external cohorts. Independent risk factors for blast transformation included DNMT3AMUT, ASXL1MUT, PHF6WT, leukocytes ≥13 x 109/L, and ≥2% circulating or ≥10% bone marrow blasts. The current study proposes an easy to implement, globally applicable, and molecularly adaptive risk model for CMML.
Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma
Maura, Francesco , Bergsagel, P. Leif , Bergsagel, P. Leif , Maura, Francesco

New England Journal of Medicine | May 7, 2025 | Volume: 392 | Issue: 18 | Pages: 1858-1860

10.1056/nejme2504273 | PMID 40334161 Get It

A human and mouse subpopulation of senescent β-cells induces pathologic dysfunction through targetable paracrine signaling
Carapeto, Priscila , Abarca, Cristian , Hela, Francesko , Sanjines, Stephanie, Pena, Sebastian, Le, Sandra M., Cahill, Christopher, Midha, Ayush , Baker, Dylan , Espinoza, Sara , Cigarroa, Francisco , Woolworth, Jillian L., Kirkland, James L. , Musi, Nicolas , Aguayo‐Mazzucato, Cristina , Iwasaki, Kanako , Carapeto, Priscila , Abarca, Cristian , Hela, Francesko , Midha, Ayush , Domanskyi, Sergii , Chuang, Jeffrey H , Kuchel, George A , Robson, Paul , Aguayo-Mazzucato, Cristina , Pena, Alejandro , Iwasaki, Kanako , Pena, Sebastian, Pan, Hui , Alcoforado Diniz, Juliana , Domanskyi, Sergii , Espinoza, Sara, Pena, Alejandro, Garovic, Vesna D. , Tchkonia, Tamar , Kuchel, George A. , Robson, Paul

No container title available | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.07.648438 | PMID 40654723 Get It

ABSTRACT Cellular senescence is a stress response mechanism marked by irreversible growth arrest, upregulation of antiapoptotic pathways, loss of cellular function, and remodelling of the cellular secretory profile. In both humans and mice, pancreatic β-cells undergo senescence with age and insulin resistance. Targeted removal of senescent cells in mouse models of diabetes improves glucose homeostasis, demonstrating the role β-cell senescence in diabetes progression. In contrast, β-cell senescence also promotes immune surveillance, promoting β-cell survival and function. Thus, a better understanding of senescent cells’ phenotypic and functional heterogeneity is needed to develop effective therapeutic strategies. Herein, we show that subpopulations of senescent β-cells in mice and humans, which were identified through the expression of Cdkn1a (encoding p21 Cip1 ) and Cdkn2a (encoding p16 Ink4a ) by single-cell RNA sequencing (scRNA-seq), flow cytometry, spatial transcriptomics, and spatial proteomics, exhibit distinct transcriptional and functional identities. The predominant senescent β-cell subpopulation expressed Cdkn1a and was characterized by a lack of glucose responsiveness, high basal insulin secretion, and transcription of canonical SASP factors. The SASP of Cdkn1a -expressing β-cells had non-cell autonomous effects on neighbouring cells. A subset of four SASP factors from Cdkn1a + cells was sufficient to induce secondary senescence and β-cell dysfunction in vitro . JAK inhibitors (JAK1/2 and JAK1/3) counteracted secondary senescence induction and restored β-cell function in high-fat diet-fed mice and human islets from donors with or without type 2 diabetes. GRAPHICAL ABSTRACT
When getting reactive becomes the nORM: the emerging roles of proinflammatory cholangiokines
Kostallari, Enis , He, Yong , Kostallari, Enis

Gut | May 7, 2025 | Volume: 75 | Issue: 3 | Pages: 432-433

10.1136/gutjnl-2025-335426 | PMID 40335160 Get It

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Wang, Jarey H. , Sherry, Alexander D. , Bazyar, Soha , Sutera, Philip , Radwan, Noura , Phillips, Ryan , Deek, Matthew P. , Lu, Jiayun , Dipasquale, Shirl, Deville, Curtiland , DeWeese, Theodore L. , Malek, Reem , Dudley, S.A. , Greco, Stephen , Denmeade, Samuel R. , Ramotar, Matthew , Leenstra, James L. , Desai, Neil , Stish, Bradley J. , Tang, Chad , Kiess, Ana P. , Phillips, Ryan , Hobbs, Robert F , Malek, Reem , Antonarakis, Emmanuel S , Marshall, Catherine H , Denmeade, Samuel , Paller, Channing J , Pienta, Kenneth J , Oz, Orhan K , Leenstra, James L , Park, Sean S , Abramowitz, Matthew C , Desai, Neil , Berlin, Alejandro , Stish, Bradley J , Tang, Chad , Tran, Phuoc T , Kiess, Ana , Deville, Curtiland , Sherry, Alexander D , Song, Daniel Y. , Wang, Hao , Antonarakis, Emmanuel S. , Marshall, Catherine H. , Paller, Channing J. , Carducci, Michael A. , Park, Sean S. , Abramowitz, Matthew C.

Journal of Clinical Oncology | May 7, 2025 | Volume: 43 | Issue: 18 | Pages: 2059-2068

10.1200/jco-25-00131 | PMID 40334149 Get It

PURPOSE Randomized clinical trials (RCTs) have shown progression-free survival (PFS) benefits of metastasis-directed therapy (MDT) without androgen deprivation therapy for oligometastatic castration-sensitive prostate cancer (omCSPC). Most patients with bone metastatic (BM) omCSPC recur with additional bone disease after MDT. We hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target subclinical bone disease and delay progression. METHODS This is an investigator-initiated, multicenter, open-label phase II RCT. Eligible men with recurrent omCSPC with ≥one bone metastasis (≤three on conventional imaging and/or ≤five on molecular imaging) were randomly assigned (1:1) to stereotactic ablative radiation (SABR) MDT alone or SABR MDT with Ra223 (six cycles). Primary end point was composite PFS. RESULTS From August 9, 2019, to March 2, 2023, 64 patients were randomly assigned, 33 to SABR MDT and 31 to SABR MDT/Ra223 balancing for key covariates. Most SABR MDT/Ra223 patients (87%) received six cycles of Ra223. The median PFS was 11.8 months with SABR MDT and 10.5 months with SABR MDT/Ra223 (adjusted hazard ratio [aHR], 1.42 [95% CI, 0.79 to 2.56]; P = .24). Seven patients (11%) experienced grade 3 treatment-related adverse events (no grade 4 or 5), 2 of 33 (6%) with SABR and 5 of 30 (17%) with SABR MDT/Ra223. Patients with high-risk (HiRi) pathogenic mutations in ATM , BRCA1/2 , RB1 , or TP53 had worse PFS (HR, 5.95 [95% CI, 1.83 to 19.3]; P = .003). Greater T-cell receptor (TCR) unique productive rearrangements were prognostic for improved PFS independent of the treatment arm (aHR, 0.45 [95% CI, 0.21 to 0.96]; P = .04). CONCLUSION Adding Ra223 to SABR MDT in BM omCSPC does not delay progression of disease. We provide evidence for an HiRi mutational signature and TCR repertoire as prognostic biomarkers in omCSPC treated with SABR MDT, highlighting the importance of collecting biological correlates in RCTs for omCSPC.